RANK expression was reported in 160 (27%) patients and correlated with high tumor grade, negative HR status, higher pathological complete response rate, and shorter DFS and OS, suggesting an association with higher chemotherapy sensitivity but also with higher relapse and death risk. This evidence concerns the gene TNFRSF11A and neoplasm.